The Nrf2-ARE Pathway: a Valuable Therapeutic Target for the Treatment of Neurodegenerative Diseases

Overview

Journal Recent Pat CNS Drug Discov

Publisher Bentham Science Publishers

Specialties Neurology
Pharmacology

Date 2012 Jun 30

PMID 22742419

Citations 105

Authors

Gururaj Joshi

Jeffrey A Johnson

Affiliations

Soon will be listed here.

Abstract

Modulation of NF-E2 related factor 2 (Nrf2) has been shown in several neurodegenerative disorders. The overexpression of Nrf2 has become a potential therapeutic avenue for various neurodegenerative disorders such as Parkinson, Amyotrophic lateral sclerosis, and Alzheimer's disease. The expression of phase II detoxification enzymes is governed by the cis-acting regulatory element known as antioxidant response element (ARE). The transcription factor Nrf2 binds to ARE thereby transcribing multitude of antioxidant genes. Keap1, a culin 3-based E3 ligase that targets Nrf2 for degradation, sequesters Nrf2 in cytoplasm. Disruption of Keap1-Nrf2 interaction or genetic overexpression of Nrf2 can increase the endogenous antioxidant capacity of the brain thereby rendering protection against oxidative stress in neurodegenerative disorders. This review primarily focuses on recent patents that target Nrf2 overexpression as a promising therapeutic strategy for the treatment of neurodegenerative disorders.

Citing Articles

Nrf2-Independent Anti-Inflammatory Effects of Dimethyl Fumarate: Challenges and Prospects in Developing Electrophilic Nrf2 Activators for Neurodegenerative Diseases.

Izumi Y, Koyama Y Antioxidants (Basel). 2025; 13(12.

PMID: 39765855 PMC: 11727036. DOI: 10.3390/antiox13121527.

Filbertone-Induced Nrf2 Activation Ameliorates Neuronal Damage via Increasing BDNF Expression.

Gong J, Kim C, Park J, Kang S, Jang Y, Kim M Neurochem Res. 2024; 50(1):44.

PMID: 39636503 PMC: 11621137. DOI: 10.1007/s11064-024-04290-x.

Neuroprotective Properties of Rutin Hydrate against Scopolamine-Induced Deficits in BDNF/TrkB/ERK/CREB/Bcl2 Pathways.

Sreelatha I, Choi G, Lee I, Inturu O, Lee H, Park Y Neurol Int. 2024; 16(5):1094-1111.

PMID: 39452684 PMC: 11510686. DOI: 10.3390/neurolint16050082.

Nrf2 and Ferroptosis: Exploring Translational Avenues for Therapeutic Approaches to Neurological Diseases.

Mohan M, Mannan A, Kakkar C, Singh T Curr Drug Targets. 2024; 26(1):33-58.

PMID: 39350404 DOI: 10.2174/0113894501320839240918110656.

exerts neuroprotective activity against quaternary metal mixture-induced memory impairment mediated by oxido-inflammatory response via Nrf2 pathway.

Orisakwe O, Ikpeama E, Orish C, Ezejiofor A, Okolo K, Cirovic A AIMS Neurosci. 2024; 11(2):118-143.

PMID: 38988888 PMC: 11230863. DOI: 10.3934/Neuroscience.2024008.

References

Zhang D, Hannink M . Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003; 23(22):8137-51. PMC: 262403. DOI: 10.1128/MCB.23.22.8137-8151.2003. View

Innamorato N, Jazwa A, Rojo A, Garcia C, Fernandez-Ruiz J, Grochot-Przeczek A . Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One. 2010; 5(7):e11838. PMC: 2911386. DOI: 10.1371/journal.pone.0011838. View

Halliwell B . Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging. 2001; 18(9):685-716. DOI: 10.2165/00002512-200118090-00004. View

Ho Y, Xiong Y, Ma W, Spector A, Ho D . Mice lacking catalase develop normally but show differential sensitivity to oxidant tissue injury. J Biol Chem. 2004; 279(31):32804-12. DOI: 10.1074/jbc.M404800200. View

Vargas M, Pehar M, Diaz-Amarilla P, Beckman J, Barbeito L . Transcriptional profile of primary astrocytes expressing ALS-linked mutant SOD1. J Neurosci Res. 2008; 86(16):3515-25. PMC: 4048747. DOI: 10.1002/jnr.21797. View

Petersen R, Thomas R, Grundman M, Bennett D, Doody R, Ferris S . Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005; 352(23):2379-88. DOI: 10.1056/NEJMoa050151. View

Goodall E, Morrison K . Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Expert Rev Mol Med. 2006; 8(11):1-22. DOI: 10.1017/S1462399406010854. View

Velichkova M, Hasson T . Keap1 regulates the oxidation-sensitive shuttling of Nrf2 into and out of the nucleus via a Crm1-dependent nuclear export mechanism. Mol Cell Biol. 2005; 25(11):4501-13. PMC: 1140621. DOI: 10.1128/MCB.25.11.4501-4513.2005. View

Sano M, Ernesto C, Thomas R, Klauber M, Schafer K, Grundman M . A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997; 336(17):1216-22. DOI: 10.1056/NEJM199704243361704. View

10.

Padmanabhan B, Scharlock M, Tong K, Nakamura Y, Kang M, Kobayashi A . Purification, crystallization and preliminary X-ray diffraction analysis of the Kelch-like motif region of mouse Keap1. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006; 61(Pt 1):153-5. PMC: 1952392. DOI: 10.1107/S1744309104032506. View

11.

Smith M, Richey Harris P, Sayre L, Beckman J, Perry G . Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci. 1997; 17(8):2653-7. PMC: 6573097. View

12.

Stack C, Ho D, Wille E, Calingasan N, Williams C, Liby K . Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med. 2010; 49(2):147-58. PMC: 2916021. DOI: 10.1016/j.freeradbiomed.2010.03.017. View

13.

Aksenov M, Aksenova M, Butterfield D, Geddes J, Markesbery W . Protein oxidation in the brain in Alzheimer's disease. Neuroscience. 2001; 103(2):373-83. DOI: 10.1016/s0306-4522(00)00580-7. View

14.

Hansen J, Go Y, Jones D . Nuclear and mitochondrial compartmentation of oxidative stress and redox signaling. Annu Rev Pharmacol Toxicol. 2006; 46:215-34. DOI: 10.1146/annurev.pharmtox.46.120604.141122. View

15.

Vargas M, Pehar M, Cassina P, Martinez-Palma L, Thompson J, Beckman J . Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival. J Biol Chem. 2005; 280(27):25571-9. DOI: 10.1074/jbc.M501920200. View

16.

Lesage S, Brice A . Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009; 18(R1):R48-59. DOI: 10.1093/hmg/ddp012. View

17.

Ischiropoulos H, Beckman J . Oxidative stress and nitration in neurodegeneration: cause, effect, or association?. J Clin Invest. 2003; 111(2):163-9. PMC: 151889. DOI: 10.1172/JCI17638. View

18.

Chanas S, Jiang Q, McMahon M, McWalter G, McLellan L, Elcombe C . Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem J. 2002; 365(Pt 2):405-16. PMC: 1222698. DOI: 10.1042/BJ20020320. View

19.

Iyanagi T, Yamazaki I . One-electron-transfer reactions in biochemical systems. V. Difference in the mechanism of quinone reduction by the NADH dehydrogenase and the NAD(P)H dehydrogenase (DT-diaphorase). Biochim Biophys Acta. 1970; 216(2):282-94. DOI: 10.1016/0005-2728(70)90220-3. View

20.

Lin S, Lisi L, Dello Russo C, Polak P, Sharp A, Weinberg G . The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro. 2011; 3(2). PMC: 3072764. DOI: 10.1042/AN20100033. View